Spliceosomic dysregulation unveils NOVA1 as a candidate actionable therapeutic target in pancreatic neuroendocrine tumors
Sergio Pedraza‐Arévalo(Instituto Maimónides de Investigación Biomédica de Córdoba), Justo P. Castaño(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), María Ángeles Gálvez-Moreno(Instituto Maimónides de Investigación Biomédica de Córdoba), Aura D. Herrera‐Martínez(Instituto Maimónides de Investigación Biomédica de Córdoba), Rafael Sánchez‐Sánchez(Instituto Maimónides de Investigación Biomédica de Córdoba), Manuel D. Gahete(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Raquel Serrano‐Blanch(Instituto Maimónides de Investigación Biomédica de Córdoba), Antonio C. Fuentes-Fayos(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Juan M. Jiménez‐Vacas(Instituto de Salud Carlos III), Sebastián Ventura(University of Córdoba), Alejandro Ibáñez‐Costa(Instituto de Salud Carlos III), Emilia Alors‐Pérez(Instituto de Salud Carlos III), Ricardo Blázquez‐Encinas(Instituto Maimónides de Investigación Biomédica de Córdoba), Raúl M. Luque(Instituto de Salud Carlos III), Óscar Reyes(Instituto Maimónides de Investigación Biomédica de Córdoba), Rosa Ortega‐Salas(Instituto Maimónides de Investigación Biomédica de Córdoba)
Cited by 22
Related Papers
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
|Pharmacological Reviews|2018|251